))
Delcath Systems: Filtering Through Its Past & Future
Fetch error
Hmmm there seems to be a problem fetching this series right now.
Last successful fetch was on October 16, 2023 23:24 (
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 337249292 series 3380517
Вміст надано Encode Ideas, L.P., Encode Ideas, and L.P.. Весь вміст подкастів, включаючи епізоди, графіку та описи подкастів, завантажується та надається безпосередньо компанією Encode Ideas, L.P., Encode Ideas, and L.P. або його партнером по платформі подкастів. Якщо ви вважаєте, що хтось використовує ваш захищений авторським правом твір без вашого дозволу, ви можете виконати процедуру, описану тут https://uk.player.fm/legal.
An interview with Gerard Michel, CEO of Delcath Systems, where Gerard reflects back on his time with Vericel, the decision to become CEO of Delcath, the initial NDA submission for the HEPZATO™ KIT, and the preliminary data release from the Phase 3 FOCUS study. Gerard also addresses the future for Delcath, including the impending full Phase 3 FOCUS results, future clinical indications to be pursued with the HEPZATO™ KIT, and commercial dynamics in the interventional oncology space.
Companies discussed during the podcast:
Delcath Systems, Inc (Nasdaq: DCTH)
Vericel Corporation (Nasdaq: VCEL)
Immunocore Ltd (Nasdaq: IMCR)
Bright Minds Biosciences (OTCQB: BMBIF, CSE: DRUG)
Gerard Michel, CEO of Delcath Systems, Inc. (“Delcath”) appeared on this episode of the podcast. Listeners are urged to review Delcath’s SEC filings and cautioned not to place undue reliance on any forward-looking statements. Delcath undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.
7 епізодів
Поширити
